Autoimmune And Rheumatic Diseases
Patients report rheumatic disease improvement after swapping certain drugs for cannabis
Nearly two-thirds of patients with rheumatic diseases reported swapping NSAIDs, opioids, sleep aids or muscle relaxants with medical cannabis, with most reporting higher symptom improvement with the cannabis, according to data.
Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine
Adalimumab combined with corticosteroids led to a significantly lower rate of relapse in Behçet’s disease uveitis vs. cyclosporine alongside corticosteroids, according to data published in The Lancet Rheumatology.
‘Devouring’ the market? Walmart to quintuple its autoimmune specialty pharmacy locations
The largest retailer in the nation has sampled a taste of the autoimmune specialty pharmacy market, and has decided it wants more.
Biosimilar retention not impacted by comorbidities in inflammatory RMDs
The presence of comorbidities with inflammatory rheumatic musculoskeletal diseases made little difference in biosimilar retention after a non-medical switch, according to data published in Arthritis Research & Therapy.
Raynaud’s disease most severe at very low temperatures, also ‘troublesome’ above 35°C
The severity of Raynaud’s disease is greatest at very low temperatures, but can also increase in hot environments that reach 35°C and above, according to data published in The Lancet Rheumatology.
Systemic treatment reduces risk for new Sjögren’s disease activity in presence of lymphoma
Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.
Dual therapy can have ‘synergistic effect’ in difficult-to-treat inflammatory diseases
SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.
‘Very little evidence’ that COVID-19 alters course of rheumatic, autoimmune diseases
SAN DIEGO — Although a flood of COVID-19 and long COVID research continues to emerge, concerns may be limited for rheumatologists, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
Severe disease, strict endpoints in CAR T trials 'could be a way through the regulators'
SAN DIEGO — Regulatory trials of chimeric antigen receptor T-cell therapies for autoimmune diseases could be successful with a focus on patients with severe disease and strict endpoints, according to a speaker.
Among herbal supplements, elderberry poses greatest risks in autoimmune skin disease
Use of elderberry as an herbal supplement preceded disease exacerbation in 62% of patients with dermatomyositis, and in 50% of those with cutaneous lupus erythematosus, according to data published in ACR Open Rheumatology.